Two-years follow-up of low-dose methotrexate and 6-methylprednisolone therapy in a patient with idiopathic retroperitoneal fibrosis

A. SILI SCAVALLI, G. DI ROCCO1, D. GIANNOTI1, G. PATRIZI1, F. FREZZOTTI1, M.G. BERNIERI2, V. CANTISANI2, A. REDLER1

Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
1Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy
2Department of Radiology, Oncology and Pathology, Sapienza University of Rome, Rome, Italy

All the Authors equally contributed to this study

Abstract. – Retroperitoneal fibrosis (RPF), also known as Ormond’s disease, is a rare fibroinflammatory disease with uncertain etiology. RPF is characterized by the presence of a particular retroperitoneal fibrotic tissue which is white, woody and involving retroperitoneal structures such as the great vessels, ureters and psoas muscle. The main complication of RPF is the obstruction of local structures such as the ureters due to the fibrosis and the treatment of this aspect represents the main challenge for this pathology. RPF medical treatment consists of corticosteroids or/and immunosuppressive therapy. We report a case of a patient affected by idiopathic RPF treated with low-dose methotrexate (MTX) and 6-methylprednisolone (6-MP) for two years, describing and confirming the effectiveness and safety of a long-term low-dose MTX and 6-MP treatment associated to ureteral Double-J stenting avoiding more invasive surgical approaches.

Key Words: Idiopathic retroperitoneal fibrosis, Methotrexate, 6-methylprednisolone, Ureteral stenting.

Introduction

Retroperitoneal fibrosis (RPF), also known as Ormond’s disease, is a rare fibroinflammatory disease with uncertain etiology and its clinical features and diagnostic appearance are very different. It was first described in 1905 by the French urologist Albarran, but it became fully recognized and established as a clinical entity only in 1948 by Ormond. The true incidence of RPF is uncertain, anyway the literature reports a range from one case per 200,000 to 500,000 people per year and a male predisposition (3:1 male/female ratio) in the fifth and sixth decade of life. RPF is characterized by the presence of a particular retroperitoneal fibrotic tissue which is white, woody and involving retroperitoneal structures such as the great vessels, ureters and psoas muscle. Usually it develops around the infrarenal part of the aorta and the iliac arteries, sometimes spread down to the pelvis and rarely it extends to the scrotum or up to the diaphragm. Retroperitoneal fibrosis is generally idiopathic (about 66% of cases), but can also be secondary to surgery, particular drugs, malignant neoplasms, radiation and infections. We can define a true idiopathic RPF when a potential specific cause or a multi-organ disease are not identified. The pathogenesis of RPF is still unclear and numerous theories have been reported such as environmental factors, immunologic process, genetic component, local inflammation and advanced atherosclerosis. Recent studies support the hypothesis that the disease may be caused by a chronic inflammatory state triggered and maintained by autoimmune responses. The surgical treatment of idiopathic RPF acts only on the ureteral obstruction without preventing disease progression and relapses and the treatment of this aspect represents the main challenge for this pathology. The ureteral entrapment is often silent and progressive and the early patients’ clinical manifestations are fever, abdominal or back pain, weight loss, asthenia, dysuria and oliguria. Since the Sixties of the last century, many medical therapies have been proposed such as corticosteroids and immunosuppressants. From the beginning of the Nineties, was introduced the tamoxifen, alone or as a second-line treatment because of its interference with the fibrogenic process. We report a case of a patient affected by idiopathic RPF treated with low-dose methotrexate (MTX) and 6-methylprednisolone (6-MP) for two years, describing and confirming...
the effectiveness and safety of a long-term low-dose MTX and 6-MP treatment associated to ureteral Double-J stenting avoiding more invasive surgical approaches.

**Case Report**

In April 2010, a 76 year old caucasian female was hospitalized in our Department due to persisting bilateral low back pain. The patient reported the removal of a thyroglossal duct cyst at age 26, appendectomy at age 40, the removal of a breast fibroadenoma at age 46 and diverticular disease. She denied any drug ingestion, autoimmune diseases, previous infections or radiotherapy. Just recovered she was almost anuric, showed pain in both renal fossae and arterial hypertension (175/110 mmHg). The following blood abnormalities were present: erytrocyte sedimentation rate (ESR) 98 mm/hr; C-reactive protein (CRP) 51 mg/dl; serum urea nitrogen 72 mg/dl; serum creatinine 4.6 mg/dl; serum potassium 6.1 mEq/L; red blood cells 3,200,000/mm³; Hb 8.9 g/dl; albumin 50.2%; alpha-1 globulins 5.2%; fibrinogen 645 mg/dL. The ultrasonography showed bilateral renal stasis with caliceal, pelvis and ureteral dilatation, and a periaortic inhomogeneous fibrous tissue. The plain abdomen and renal radiography showed a bilateral hydronephrosis and a radiopaque periaortic mass such as a fibrotic tissue. An abdominal computed tomography (CT) scan revealed in the retroperitoneal space, in the prevertebral area, a fibrous tissue surrounding the aorta, vena cava, the ureters and psoas muscles. The periaortic fibrous tissue (cross diameter of 5.7 cm, front-back diameter of 3.4 cm) extends up to the pelvis and encased both ureters and was compatible with the diagnosis of retroperitoneal fibrosis (Figure 1). MRI was also performed to better document some aspects of the disease. The patient was, therefore, subjected to placement of left nephrostomy and the renal failure was gradually reduced. Our team of rheumatologists confirmed the diagnosis of idiopathic RPF and required further blood tests before starting drug treatment. The patient had positive antinuclear antibodies (ANA). Then she started the therapy with low-dose MTX at a weekly dose of 10 mg and low-dose 6-methylprednisolone (6-MP) therapy (4 mg/daily). After a week of starting therapy she was submitted to the positioning of ureteral Double-J stenting. After ten days of treatment the patient was completely asymptomatic, all blood tests were normal and then she was discharged. The CT scan performed in April of 2011 showed a good reduction of the fibrotic mass and then the urologist decided to remove the ureteral stents. Two years after the diagnosis of idiopathic RPF, the patient is completely asymptomatic and the abdominal CT scan has showed a complete reduction of the retroperitoneal fibrotic mass without any sign of relapse (Figure 2).

**Discussion**

RPF is a rare fibroinflammatory disease with uncertain etiology, characterized by the presence of a particular retroperitoneal fibrotic tissue...
which is white, woody and involving retroperitoneal structures such as the great vessels, ureters and psoas muscle. When the fibrotic mass has a large extension, it can obstruct the ureters. Specimens collected early in the course of the disease are constituted by collagen bundles, fibroblasts, plasma cells and lymphocytes, confirming that the basis of the disease is an exuberant immunologic processes. In the early phases, there is an inflammatory infiltrate of both B (CD 20+) and T (CD 4+) lymphocytes, plasma cells, macrophages (CD68+) and histiocytes and sometimes fibrinoid necrosis of medium-sized and capillary retroperitoneal vessels is also detected. As a possible genetic predisposition of idiopathic RPF, besides the old association with HLA-B27 antigen, a further clue has been studied because of its significant association with HLA-DRB1*03, an allele linked to other autoimmune diseases. The most common symptoms are low back or abdominal pain and sometimes fever. Blood tests may often show raised acute phase reactants as ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), α2-globulins which reflect the disease activity, its natural course and the eventual relapses. The laboratory tests include the complete blood count, renal function profile (creatinine levels, serum electrolyte concentration), the assay of antineutrophil cytoplasmatic antibodies (ANCA), antinuclear antibodies (ANA), anti-thyroglobulin antibodies, anti-smooth muscle antibodies (ASMA), rheumatoid factor, and furthermore IgG and IgG4 serum levels. To reach the correct diagnosis CT and MRI are very useful and in doubtful cases a biopsy is performed. More recently FDG-PET and PET/CT are feasible and suitable imaging methods useful to reach a correct diagnosis and to monitor the response to therapy. In complicated cases or unresponsive to therapy, the ureteral stenting may not be sufficient and then a surgical treatment is necessary. The surgical treatment of choice is laparoscopic or open ureterolysis; the ureter is dissected free from the fibrotic mass laterally or intraperitoneally. There is also an alternative technique through which the ureter is wrapped with omentum to avoid the entrapment by the fibrosis. Currently with the introduction of robotic surgery, some surgeons have begun to use it for the ureterolysis. The surgical or endoscopic (ureteral stenting) treatment must be combined with drug therapy in order to avoid relapses of disease. Some Authors combine corticosteroid and immunosuppressive therapy. Others give only corticosteroid or immunosuppressive agents. Kisiel B et al. showed azathioprine to be particularly effective in the treatment of RPF. Multi-targeted bio-therapy as TNF-α blocking antibodies, Jaks-STATS complex inhibitors and anti-human CD20 antibodies, either alone or combined with steroids/immunosuppressants, could represent an interesting and challenging approach for the management of idiopathic RPF. Actually there are many studies about the therapeutic potential of F8-IL10 (antibody F8 fused to anti-inflammatory IL10) and the use of phosphodiesterase-4 (PDE4) inhibitors. As reported from Alberti, in the last two decades we did not have any interesting innovation about diagnosis and therapy of RPF but only many pathogenetic news. The prognosis of RPF is surprisingly good with treatment. However, the disease may be very insidious with unpredictable progression. All the authors agree that RPF may persist or recur also some years later and a strict follow-up is necessary all life long. The rapid clinical and laboratory improvement and the progressive reduction of the fibrotic tissue, shown by CT scan, in this case report, lead us to affirm and confirm (as in our first experience of 1995) that long-term low-dose MTX and 6 MP therapy is a particularly safe and effective therapy on idiopathic RPF which avoids more invasive surgical treatments.

References


